Zostavax

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Prevention of : Herpes-Zoster

Conditions

Prevention of : Herpes-Zoster

Trial Timeline

Oct 26, 2007 → Jun 3, 2009

NCT ID

NCT00561080

About Zostavax

Zostavax is a phase 3 stage product being developed by Merck for Prevention of : Herpes-Zoster. The current trial status is completed. This product is registered under clinical trial identifier NCT00561080. Target conditions include Prevention of : Herpes-Zoster.

What happened to similar drugs?

9 of 20 similar drugs in Prevention of : Herpes-Zoster were approved

Approved (9) Terminated (0) Active (11)

✅RaltegravirMerckApproved

✅Meningococcal C conjugate vaccineNovartisApproved

✅Boostrix + Placebo (Saline)NovartisApproved

✅Meningococcal C conjugate vaccineNovartisApproved

✅Lenacapavir long-actingGilead SciencesApproved

✅DescovyGilead SciencesApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01391546	Phase 3	Completed	Jun 20, 2011	Oct 15, 2012	Herpes Zoster
NCT01328548	Pre-clinical	Completed	May 1, 2011	Mar 1, 2015	Immune System Diseases
NCT00561080	Phase 3	Completed	Oct 26, 2007	Jun 3, 2009	Prevention of : Herpes-Zoster

Competing Products

20 competing products in Prevention of : Herpes-Zoster

See all competitors

Product	Company	Stage	Hype Score
mRNA-1944	Moderna	Phase 1	0
Gam-COVID-Vac	Dr. Reddy's Laboratories	Phase 2/3	31
edoxaban + enoxaparin sodium	Daiichi Sankyo	Phase 3	40
Mifepristone	Eli Lilly	Phase 2	35
EXANTA	AstraZeneca	Phase 2	27
Risk of low dose aspirin discontinuation	AstraZeneca	Pre-clinical	26
DAPA/MET XR + DAPA + MET XR	AstraZeneca	Phase 3	40
Esomeprazole + Placebo	AstraZeneca	Phase 3	40
PCV15	Merck	Pre-clinical	18
Raltegravir	Merck	Approved	43
RotaTeq (V260) + IPV	Merck	Phase 3	40
V501	Merck	Phase 3	40
V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920	Merck	Phase 3	40
Letermovir + Placebo	Merck	Phase 3	40
Meningococcal C conjugate vaccine	Novartis	Approved	43
Enteric-coated mycophenolate sodium	Novartis	Phase 3	40
Meningococcal C conjugate vaccine	Novartis	Approved	43
rMenB+OMV NZ	Novartis	Phase 3	40
Enteric-Coated Mycophenolate Sodium	Novartis	Phase 3	40
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5ml	Novartis	Phase 3	44